Consensus NovoCure Limited

Stocks

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 23:00:00 30/09/2026 +03			5-day change	1st Jan Change
15.95 ^USD	-0.25%		-1.85%	+23.36%

09-23	US companies face rise in cyber attacks	RE
09-14	NovoCure Limited Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 03:20 PM

Evolution of the Average Target: NovoCure Limited

Evolution of the Target Price: NovoCure Limited

Changes in Analyst Recommendations: NovoCure Limited

7d8a.o7xWS5CSHAqfrGV2coJYu7D1zQcvm5qqEsuIKErM38U.5fsEeM_UaWXpzlwEH68p6PedpGRu3vjhULrMHQSujYTw9Q4gpdgvY8j1IA~974db7981f05a63b2e72f99be89f2b53

Analysts' recommendations: NovoCure Limited

07-24	Wedbush Adjusts Price Target on NovoCure to $20 From $18, Maintains Neutral Rating	MT
25/07/25	NovoCure Shares Fall After Wells Fargo Downgrade	MT
25/07/25	Wells Fargo Downgrades NovoCure to Equalweight From Overweight, Adjusts Price Target to $14.50 From $40	MT
24/07/25	Wedbush Cuts Price Target on NovoCure to $18 From $27, Maintains Neutral Rating	MT
08/07/25	Ladenburg Thalmann Initiates NovoCure at Buy With $30 Price Target	MT
02/12/24	HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	MT
02/12/24	Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating	MT
02/12/24	Evercore ISI Upgrades NovoCure to Outperform	MT
16/10/24	HC Wainwright Upgrades NovoCure to Buy From Neutral, Adjusts Price Target to $30 From $24	MT
04/06/24	Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating	MT
10/04/24	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT
03/04/24	Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating	MT
23/02/24	Evercore ISI Adjusts Price Target on NovoCure to $15 From $14, Keeps In Line Rating	MT
26/10/23	Wedbush Adjusts NovoCure Price Target to $21 From $23, Maintains Neutral Rating	MT
29/08/23	Wells Fargo Adjusts NovoCure's Price Target to $49 From $102, Keeps Overweight Rating	MT
28/08/23	Wedbush Cuts NovoCure's Price Target to $23 From $46 After Drug Failure in Clinical Study, Maintains Neutral Rating	MT
28/08/23	HC Wainwright Downgrades NovoCure to Neutral From Buy, Cuts Price Target to $25 From $85	MT
28/08/23	Piper Sandler Lowers Price Target on NovoCure to $35 From $45, Maintains Overweight Rating	MT
28/08/23	Wedbush Cuts NovoCure's Price Target to $23 From $46, Maintains Neutral Rating	MT
08/08/23	Piper Sandler Upgrades NovoCure to Overweight From Neutral, Price Target is $45	MT
04/08/23	SVB Securities Initiates NovoCure at Outperform With $51 Price Target	MT
31/07/23	Evercore ISI Upgrades NovoCure to In Line From Underperform, Price Target is $33	MT
07/06/23	Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	MT
07/06/23	Piper Sandler Adjusts Price Target on NovoCure to $62 From $67, Maintains Neutral Rating	MT
07/06/23	Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	MT

More recommendations

Medical Equipment

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	NOVOCURE LIMITED					+70.17%
	ABBOTT LABORATORIES					+21.69%
	MEDTRONIC PLC					+21.49%
	STRYKER CORPORATION					+33.56%
	ESSILORLUXOTTICA					+59.76%
	CENCORA, INC.					+22.98%
	BECTON, DICKINSON AND COMPANY					+9.31%
	HOYA CORPORATION					+28.07%
	IDEXX LABORATORIES, INC.					+34.31%
	DEXCOM, INC.					+9.49%
	Average					+31.08%
	Weighted average by Cap.					+27.63%